WO1994003201A1 - Parathyroid hormone fragments and analogs - Google Patents

Parathyroid hormone fragments and analogs Download PDF

Info

Publication number
WO1994003201A1
WO1994003201A1 PCT/US1993/007375 US9307375W WO9403201A1 WO 1994003201 A1 WO1994003201 A1 WO 1994003201A1 US 9307375 W US9307375 W US 9307375W WO 9403201 A1 WO9403201 A1 WO 9403201A1
Authority
WO
WIPO (PCT)
Prior art keywords
pth
parathyroid hormone
subject
treatment
human parathyroid
Prior art date
Application number
PCT/US1993/007375
Other languages
French (fr)
Inventor
Sandra R. Hilliker
Original Assignee
Hilliker Sandra R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hilliker Sandra R filed Critical Hilliker Sandra R
Priority to EP93919895A priority Critical patent/EP0656784A4/en
Priority to JP6505568A priority patent/JPH08503692A/en
Publication of WO1994003201A1 publication Critical patent/WO1994003201A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to parathyroid hormone peptides and their use in treating bone disease.
  • this invention relates to human parathyroid hormone peptide fragments and analogs which stimulate bone formation without the undesirable side effects associated with known parathyroid hormone peptides.
  • Degenerative bone disease such as osteoporosis
  • osteoporosis is the most frequently occurring disease of the skeletal system. It is characterized by an imbalance in cell biological activity between bone formation and bone resorption which results in a reduction of bone mass.
  • the problems involved ' in treating osteoporosis and conditions of reduced bone mass are largely unresolved. This is especially true in cases where a considerable reduction of bone mass has occurred and remodeling of the bone has decreased, as seen in the late stages of osteoporosis.
  • Successful treatment should not only prevent progression of the disease, but should also stimulate new bone formation.
  • Present treatment of osteoporosis includes hormone therapy, calcium and vitamin D supplements and sodium fluoride treatment, which for the most part are unsatisfactory.
  • Bone loss may be slowed down by such treatment, but the total net gain in bone mass is limited.
  • the parathyroid hormone (PTH) regulates calcium and phosphorus metabolism and has a potent effect on bone metabolism.
  • Administration of PTH induces a rapid proliferation of osteoclast cells associated with bone destruction, as well as a slower stimulation of osteoblast cells, which are necessary for bone formation.
  • the first 34 N-terminal amino acids, (1-34)PTH of the 84 amino acids, which make up PTH, are responsible for nearly all of the biological activity of the native hormone. Numerous clinical trials and experimental work have shown that both PTH and (1-34JPTH are only of very limited clinical value in treating osteoporosis.
  • human parathyroid hormone fragments in which the C-terminal amino acid is amino acid 35 to 38, preferably 37 or 38 and at least the first N-terminal amino acid has been removed, and analogs and derivatives thereof stimulate osteoblast activity and maximize bone formation without undesirable levels of bone resorption, antibody formation, or tachiphylaxis.
  • the human parathyroid hormone fragments of this invention can be represented in accordance with standard nomenclature by the formula (m-n)PTH, where is the number of the first N-terminal amino acid and is at least 2 in the present invention and n is amino acid 35 to 38.
  • ⁇ t is 2 to 28 and comprise;
  • (3-37)PTH (4-37JPTH, (5-37JPTH, (6-37JPTH, (7-37)PTH, (8-37)PTH, (9-37)PTH, (10-37)PTH, (11-37)PTH, (12-37)PTH, (13-37)PTH, (14-37)PTH, (15-37)PTH, (16-37)PTH, (17-37)PTH, (18-37JPTH, (19-37)PTH, (20-37)PTH, (21-37)PTH, (22-37)PTH, (23-37)PTH, (24-37)PTH, (25-37)PTH, (26-37)PTH, (27-37)PTH, or (28-37)PTH, ' especially (3-37)PTH;
  • PTH is human parathyroid hormone (hPTH), or a pharmaceutically acceptable salt or hydrolysable ester thereof.
  • the compounds of the invention are prepared by the known techniques, for example, the solid-phase peptide synthesis developed by Merrified ("Solid Phase Peptide Synthesis", Advances in Enzymology, 32:221-296, 1969).
  • the C-terminal amino acid of the peptide is linked covalently via the carboxyl group to a solid support.
  • the desired peptide sequence is prepared by stepwise coupling of single amino acids in protected form, if necessary, to a peptide chain growing from the carboxyl toward the amino terminus. Because each amino acid is coupled by nearly the same series of reactions, the need for elaborate strategies in the synthesis is minimized. The method is rapid; and after preparation of the desired peptide chain, the peptide can be easily deprotected by standard techniques, where necessary.
  • the peptide fragment can be prepared using recombinant DNA technology.
  • the DNA for the desired peptide can be synthesized with a commercially available oligonucleotide synthesizer (gene machine), such as Applied Biosyste Inc. automated synthesizer, using the manufacturer's procedure.
  • the DNA is then expressed using a suitable vector in a conventional host, such as E coli ' , yeast or a mam alion cell to yield the desired peptide fragment.
  • the above parathyroid hormone peptides are- useful in stimulating bone formation as indicated in male or female rats weighing more than 50 grams given doses of peptide between 100 ug/kg body weight and 1000 ug/kg body weight per day.
  • the animals are divided into five groups of 12 animals each and given subcutaneous injections daily for up to one month.
  • Group 1 is the placebo control;
  • group 2 receives 100 ug/kg/day of the standard (l-38)hPTH;
  • group 3 receives 100 ug/kg/day of peptide;
  • group 4 receives 400 ug/kg/day of peptide; and
  • group 5 receives 1000 ug/kg/day of peptide.
  • the levels of serum proteins and enzymes which reflect changes in bone metabolism are assayed at the end of treatment (e.g. serum osteocalcin, serum alkaline phosphatase, and serum tartrate resistant acid phosphatase) .
  • All animals receive tetracycline compounds during the last week of treatment: (1) either [ 3 H]-tetra ⁇ cycline at 25 uCi/100 g body weight to measure radioisotope incorporation into bone; or (2) two injections of tetra ⁇ cycline compounds - the first injection four to five days before sacrifice and the second injection one to two days before sacrifice - to fluorescently label newly mineralizing cancellous bone for the measurement of mineral apposition rate/bone formation rate by morphometry.
  • Animals are sacrificed at the end of treatment and femurs, vertebrae, and tibias collected for either radioisotopic or morphometric analysis of cancellous and/or cortical bone and for the analysis of bone extracts (e.g. alkaline phosphatase and tartrate resistant acid phosphatase).
  • bone extracts e.g. alkaline phosphatase and tartrate resistant acid phosphatase.
  • the PTH hormone fragments, analogs, and derivatives of this invention are therefore useful in treating 1 degenerative bone disease and provide a method of treating osteoporosis or hypercalcemia through the administration of a therapeutically effective amount of a parathyroid hormone peptide of the invention to a subject in need of said treatment.
  • the invention provides a method of treating hyperparathyroidi ⁇ m, in particular, hyperparathyroidism expressed as a hypercalcemic crisis, renal failure, or hypertension, which comprises administering to a subject in need of said treatment a therapeutically effective amount of a parathyroid hormone peptide of the invention.
  • This invention further provides a method of treating the disease state produced by a tumor or other aberrant cell overproducing a peptide hormone-like molecule and a method of treating immune diseases wherein the disease state comprises inflammation, an allergic response, or hyperactive lymphocytes comprising the administration of a therapeutically effective amount of a peptide hormone fragment, analog, or derivative of the present invention to a subject in need of said treatment.
  • the amount of parathyroid hormone peptide of the invention administered for the above uses will vary depending on the peptide used and the subject undergoing treatment. However, satisfactory results are obtained when the peptide is administered daily or intermittently, and, if desirable, in- 4-week or 6-week cycles followed by peptide free periods of 1 to 4 weeks.
  • the peptides of the invention may be administered, in particular, to osteoporotic subjects or those with reduced bone mass, e.g., humans, in a dosage range of 20-2000 ⁇ g/day, preferably 100-1000 ⁇ g/day. It may be administered in a single dose or in several doses over 24 hours or as a continuous intravenous infusion.
  • the peptides of the invention are administered enterally, parenterally, or subcutaneously admixed with conventional pharmaceutical carriers. They may be administered orally in the form of tablets or capsules or parenterally as solutions, e.g., sterile injectable solution, suspensions, e.g., aqueous suspension, or in depot form, in which the active ingredient is coated by known techniques to delay disintegration and absorption and thereby provide a sustained action over large periods of time.' They may also be administered nasally in the form of sprays or rectally in the form of suppositories or enemas. They are preferably administered subcutaneously or rectally and especially nasally, since they do not stimulate bone resorption and cause erosion of the nasal cartilage.
  • the smaller PTH fragments in which m is 18 to 28 are particularly useful for nasal administration, because they are more readily absorbed through the nasal membrane.
  • the pharmaceutical compositions of the invention are formulated as disclosed in the art and may contain up to about 90% of the active ingredients in combination with the carrier or adjuvant.
  • parathyroid hormone fragment (3-38) PTH is carried out by the solid phase method of Merrifield using a peptide synthesizer.
  • Tertiary butyloxycarbonyl (Boc) group is used to protect the al-pha-amino group of each amino acid during coupling.
  • the peptide-resin synthesis is carried out using the synthesizer manufacturer's specified protocols. After synthesis is complete, the peptide is deprotected, cleaved from the copoly er resin, and purified in accordance with the manufacturer's protocol to yield (3-38)PTH.

Abstract

This invention relates to human parathyroid hormone fragment in which the C-terminal amino acid is amino acid 35 to 38 and at least the first N-terminal amino acid has been removed or an analog or derivative thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof and their use in treating bone degenerative diseases.

Description

PARATHYROID HORMONE FRAGMENTS AND ANALOGS
This invention relates to parathyroid hormone peptides and their use in treating bone disease. In particular/ this invention relates to human parathyroid hormone peptide fragments and analogs which stimulate bone formation without the undesirable side effects associated with known parathyroid hormone peptides.
Degenerative bone disease, such as osteoporosis, is the most frequently occurring disease of the skeletal system. It is characterized by an imbalance in cell biological activity between bone formation and bone resorption which results in a reduction of bone mass. The problems involved ' in treating osteoporosis and conditions of reduced bone mass are largely unresolved. This is especially true in cases where a considerable reduction of bone mass has occurred and remodeling of the bone has decreased, as seen in the late stages of osteoporosis. Successful treatment should not only prevent progression of the disease, but should also stimulate new bone formation. Present treatment of osteoporosis includes hormone therapy, calcium and vitamin D supplements and sodium fluoride treatment, which for the most part are unsatisfactory. Bone loss may be slowed down by such treatment, but the total net gain in bone mass is limited. It has been known for some time that the parathyroid hormone (PTH) regulates calcium and phosphorus metabolism and has a potent effect on bone metabolism. Administration of PTH however, induces a rapid proliferation of osteoclast cells associated with bone destruction, as well as a slower stimulation of osteoblast cells, which are necessary for bone formation. It is also well established that the first 34 N-terminal amino acids, (1-34)PTH, of the 84 amino acids, which make up PTH, are responsible for nearly all of the biological activity of the native hormone. Numerous clinical trials and experimental work have shown that both PTH and (1-34JPTH are only of very limited clinical value in treating osteoporosis. This is because of poor, inconsistent and unpredictable total net gain in bone mass, due to their stimulating osteoclastic activity as well as osteoblastic activity. In addition, continued use of PTH or (1-34) PTH induces tachiphylaxis within 12 to 18 months after treatment starts. Removal of the first one or two amino acids is known to reduce the activities of PTH and (1-34) PTH associated with stimulation of osteoclasts and bone resorption in vitro. It has been suggested that the parathyroid hormone fragment (3-34) PTH would stimulate osteoblast proliferation and bone formation without concurrent bone resorption. However, (3-34) PTH has antigenic activity and tachiphylaxis similar to (1-34) PTH, which cause undesirable antibody formation and resistance to the treatment. All of the presently known PTH fragments and analogs are of limited value in the treatment of osteoporosis, because of their bone resorption activity, antigenicity or tachiphylaxis.
It has now been found that human parathyroid hormone fragments, in which the C-terminal amino acid is amino acid 35 to 38, preferably 37 or 38 and at least the first N-terminal amino acid has been removed, and analogs and derivatives thereof stimulate osteoblast activity and maximize bone formation without undesirable levels of bone resorption, antibody formation, or tachiphylaxis. 'The human parathyroid hormone fragments of this invention can be represented in accordance with standard nomenclature by the formula (m-n)PTH, where is the number of the first N-terminal amino acid and is at least 2 in the present invention and n is amino acid 35 to 38. In the preferred PTH fragments, analogs, and derivatives, πt is 2 to 28 and comprise;
a) (3-38)PTH, (4-38)PTH, (5-38)PTH, (6-38)PTH, (7-38)PTH, (8-38)PTH, (9-38)PTH, (10-38)PTH, (11-38)PTH, (12-38)PTH. 13-38)PTH, (14-38)PTH, (15-38)PTH, (16-38)PTH, (17-38)PTH, (18-38)PTH, (19-38)PTH, (20-38)PTH, (21-38)PTH, (22-38)PTH, (23-38)PTH, (24-38)PTH, (25-38JPTH, (26-38)PTH, (27-38)PTH, or (28-38)PTH, especially (3-38)PTH;
b) (3-37)PTH, (4-37JPTH, (5-37JPTH, (6-37JPTH, (7-37)PTH, (8-37)PTH, (9-37)PTH, (10-37)PTH, (11-37)PTH, (12-37)PTH, (13-37)PTH, (14-37)PTH, (15-37)PTH, (16-37)PTH, (17-37)PTH, (18-37JPTH, (19-37)PTH, (20-37)PTH, (21-37)PTH, (22-37)PTH, (23-37)PTH, (24-37)PTH, (25-37)PTH, (26-37)PTH, (27-37)PTH, or (28-37)PTH,' especially (3-37)PTH;
c) (2-35)PTH, (2-36)PTH, (2-37)PTH, or (2-38)PTH, especially (2-37)PTH and (2-38)PTH;
d) a [Tyr34], [Nle 8,18 Tyr34], [Phe23], (Leu23],
[Nle23], [Val23], [Tyr23], (alpha-naphthyalanine23) , or [beta-naphthyalanine 23] analog of a), b) or c); or
(e) a C-terminal amide derivative of a), b) , c) or d), where PTH is human parathyroid hormone (hPTH), or a pharmaceutically acceptable salt or hydrolysable ester thereof.
The compounds of the invention are prepared by the known techniques, for example, the solid-phase peptide synthesis developed by Merrified ("Solid Phase Peptide Synthesis", Advances in Enzymology, 32:221-296, 1969). The C-terminal amino acid of the peptide is linked covalently via the carboxyl group to a solid support. The desired peptide sequence is prepared by stepwise coupling of single amino acids in protected form, if necessary, to a peptide chain growing from the carboxyl toward the amino terminus. Because each amino acid is coupled by nearly the same series of reactions, the need for elaborate strategies in the synthesis is minimized. The method is rapid; and after preparation of the desired peptide chain, the peptide can be easily deprotected by standard techniques, where necessary.
Alternatively, the peptide fragment can be prepared using recombinant DNA technology. The DNA for the desired peptide can be synthesized with a commercially available oligonucleotide synthesizer (gene machine), such as Applied Biosyste Inc. automated synthesizer, using the manufacturer's procedure. The DNA is then expressed using a suitable vector in a conventional host, such as E coli', yeast or a mam alion cell to yield the desired peptide fragment.
The above parathyroid hormone peptides are- useful in stimulating bone formation as indicated in male or female rats weighing more than 50 grams given doses of peptide between 100 ug/kg body weight and 1000 ug/kg body weight per day. The animals are divided into five groups of 12 animals each and given subcutaneous injections daily for up to one month. Group 1 is the placebo control; group 2 receives 100 ug/kg/day of the standard (l-38)hPTH; group 3 receives 100 ug/kg/day of peptide; group 4 receives 400 ug/kg/day of peptide; and group 5 receives 1000 ug/kg/day of peptide. For each group of animals, the levels of serum proteins and enzymes which reflect changes in bone metabolism are assayed at the end of treatment (e.g. serum osteocalcin, serum alkaline phosphatase, and serum tartrate resistant acid phosphatase) . All animals receive tetracycline compounds during the last week of treatment: (1) either [3H]-tetra¬ cycline at 25 uCi/100 g body weight to measure radioisotope incorporation into bone; or (2) two injections of tetra¬ cycline compounds - the first injection four to five days before sacrifice and the second injection one to two days before sacrifice - to fluorescently label newly mineralizing cancellous bone for the measurement of mineral apposition rate/bone formation rate by morphometry. Animals are sacrificed at the end of treatment and femurs, vertebrae, and tibias collected for either radioisotopic or morphometric analysis of cancellous and/or cortical bone and for the analysis of bone extracts (e.g. alkaline phosphatase and tartrate resistant acid phosphatase).
The PTH hormone fragments, analogs, and derivatives of this invention are therefore useful in treating1 degenerative bone disease and provide a method of treating osteoporosis or hypercalcemia through the administration of a therapeutically effective amount of a parathyroid hormone peptide of the invention to a subject in need of said treatment. In addition, the invention provides a method of treating hyperparathyroidiεm, in particular, hyperparathyroidism expressed as a hypercalcemic crisis, renal failure, or hypertension, which comprises administering to a subject in need of said treatment a therapeutically effective amount of a parathyroid hormone peptide of the invention. This invention further provides a method of treating the disease state produced by a tumor or other aberrant cell overproducing a peptide hormone-like molecule and a method of treating immune diseases wherein the disease state comprises inflammation, an allergic response, or hyperactive lymphocytes comprising the administration of a therapeutically effective amount of a peptide hormone fragment, analog, or derivative of the present invention to a subject in need of said treatment.
The amount of parathyroid hormone peptide of the invention administered for the above uses will vary depending on the peptide used and the subject undergoing treatment. However, satisfactory results are obtained when the peptide is administered daily or intermittently, and, if desirable, in- 4-week or 6-week cycles followed by peptide free periods of 1 to 4 weeks. The peptides of the invention may be administered, in particular, to osteoporotic subjects or those with reduced bone mass, e.g., humans, in a dosage range of 20-2000 μg/day, preferably 100-1000 μg/day. It may be administered in a single dose or in several doses over 24 hours or as a continuous intravenous infusion. During and after therapy all parameters of calcium-metabolism which may be influenced by the parathyroid peptide should be determined. Thus bone, intestine, and kidney calcium metabolism as well as 1,25-(OH)--vitamin D synthesis should be monitored to determine the effectiveness of the therapy and possible metabolic side effects.
The peptides of the invention are administered enterally, parenterally, or subcutaneously admixed with conventional pharmaceutical carriers. They may be administered orally in the form of tablets or capsules or parenterally as solutions, e.g., sterile injectable solution, suspensions, e.g., aqueous suspension, or in depot form, in which the active ingredient is coated by known techniques to delay disintegration and absorption and thereby provide a sustained action over large periods of time.' They may also be administered nasally in the form of sprays or rectally in the form of suppositories or enemas. They are preferably administered subcutaneously or rectally and especially nasally, since they do not stimulate bone resorption and cause erosion of the nasal cartilage. The smaller PTH fragments in which m is 18 to 28 are particularly useful for nasal administration, because they are more readily absorbed through the nasal membrane. The pharmaceutical compositions of the invention are formulated as disclosed in the art and may contain up to about 90% of the active ingredients in combination with the carrier or adjuvant.
Example 1 Synthesis of (3-381PTH
The synthesis of parathyroid hormone fragment (3-38) PTH is carried out by the solid phase method of Merrifield using a peptide synthesizer. Tertiary butyloxycarbonyl (Boc) group is used to protect the al-pha-amino group of each amino acid during coupling. Other functional side groups are protected as follows: (a) the hydroxyl group of serine is protected as the O-benzyl ether; (b) the hydroxyl group of tyrosine as the 0-2,6-dichlorobenzyl ether or p-bromobenzyloxycarbonyl ester; (c) the carboxyl group of glutamic and aspartic acid as the benzyl or cyclohexyl ester; (d) the imidazole nitrogen of histidine by the benzyloxymethyl (BOM) group; (e) the guanidine function of arginine by the p-toluenesulfonyl group and; f) the indole imine of tryptophane by the formyl group. The peptide-resin synthesis is carried out using the synthesizer manufacturer's specified protocols. After synthesis is complete, the peptide is deprotected, cleaved from the copoly er resin, and purified in accordance with the manufacturer's protocol to yield (3-38)PTH.
Following the above procedure (2-35)PTH, (2-36)PTH, (2-37)PTH, (2-38)PTH, (4-38)PTH, (5-38)PTH, (6-38)PTH, (7-38)PTH, (8-38)PTH, (9-38)PTH, (10-38)PTH, (11-38)PTH, (12-38)PTH, (13-38)PTH, (14-38)PTH, (15-38)PTH, (16-38JPTH, (17-38)PTH, (18-38)PTH, (19-38)PTH, (20-38)PTH, (21-38)PTH, (22-38)PTH, (23-38)PTH, (24-38)PTH, (25-38)PTH, (26-38)PTH, (27-38)PTH, (28-38)PTH, (3-37)PTH, (4-37)PTH, (5-37JPTH, (6-37)PTH, (7-37)PTH, (8-37)PTH, (9-37)PTH, (10-37)PTH, (11-37)PTH, (12-37)PTH, (13-37JPTH, (14-37)PTH, (15-37)PTH, (16-37)PTH, (17-37)PTH, (18-37)PTH, (19-37)PTH, (20-37)PTH, (21-37JPTH, (22-37)PTH, (23-37)PTH, (24-37)PTH, (25-37)PTH, (26-37)PTH, (27-37JPTH, or (28-37)PTH are similarly sythesized.

Claims

What is claimed is:
1. A human parathyroid hormone fragment in which the C-terminal amino acid is amino acid 35 to 38 and at least the first N-terminal amino acid has been removed or an analog or derivative thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof.
2. A human parathyroid hormone fragment according to claim 1, which is (m-n)PTH, where m is 2 to 28 and n is 35 to 38, or an analog or derivative thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof.
3. A human parathyroid hormone fragment according to claim 1, which is (m-n)PTH, where m is 2 to 28 and n is 37 or 38, or an analog or derivative thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof.
4. An analog according to claim 2, which is the
[Tyr34], [Nle8'18 Tyr34), [Phe23], [Leu23], [Nle23), [Val23],
[Tyr 23), [alpha-naphthylalanine23) or [beta-naphthylalanine 23] analog of (m-n)PTH or a derivative thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof.
5. A derivative according to claim 2, which is the C-terminal amide derivative of ( -n)PTH or an analog thereof or a pharmaceutically acceptable salt or hydrolysable ester thereof.
6. The human parathyroid hormone fragment according to claim 1, which is (2-38)PTH.
7. The human parathyroid hormone fragment according to claim 1, which is (3-38)PTH.
8. The human parathyroid hormone fragment- according to claim 1, which is (2-35)PTH.
9. The human parathyroid hormone fragment according to claim 1, which is (2-36)PTH.
10. The human parathyroid hormone fragments according to claim 1, which is (2-37)PTH.
11. The human parathyroid hormone fragment according to claim 1, which is (3-37)PTH.
12. The human parathyroid hormone fragment according to claim 19, which is (4-38)PTH, (5-38)PTH, (6-38)PTH, (7-38)PTH, (8-38)PTH, (9-38)PTH, (10-38)PTH, (11-38)PTH, (12-38)PTH, (13-38)PTH, (14-38)PTH, (15-38JPTH, (16-38)PTH, (17-38)PTH, (18-38)PTH, (19-38)PTH, (20-38)PTH, (21-38)PTH, (22-38)PTH, (23-38)PTH, (24-38)PTH, (25-38)PTH, (26-38JPTH, (27-38)PTH, or (28-38)PTH.
13. The human parathyroid hormone fragment according to claim 1, which is (4-37)PTH, (5-37)PTH, (6-37)PTH, (7-37)PTH, (8-37)PTH, (9-37)PTH, (10-37)PTH, (11-37)PTH, (12-37)PTH, (13-37)PTH, (14-37)PTH, (15-37)PTH, (16-37JPTH, (17-37)PTH, (18-37)PTH, (19-37)PTH, (20-37)PTH, (21-37)PTH, (22-37)PTH, (23-37)PTH, (24-37)PTH, (25-37)PTH, (26-37)PTH, (27-37)PTH, or (28-37)PTH.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
15. A pharmaceutical composition for nasal administration comprising a therapeutically effective amount of a compound according to claim 2 in which m is 18 to 28 and n is 35 to 38 and a pharmaceutically acceptable nasal carrier therefor.
16. A pharmaceutical composition for nasal administration comprising a therapeutically effective amount of a compound according to claim 2 in which m is 18 to 28 and n is 37 or 38 and a pharmaceutically acceptable nasal carrier therefor.
17. A method of treating bone degeneration in a subject in need of said treatment, which comprises administering to the subject an anti-bone degeneration effective amount of a compound according to claim 1.
18. A method of stimulating bone formation in a subject in need of said treatment, which comprises administering to the subject an amount of a compound according to claim 1 effective for stimulating bone formation.
19. A method of treating osteoporosis in a subject in need of said treatment, which comprises administering to the subject an amount of a compound according to claim 1 effective for the treatment of osteoporosis.
20. A method of treating osteoporosis in a subject in need of said treatment, which comprises nasally administering to the subject an amount effective for the treatment of osteoporosis of a compound according to claim 2 in which m is 18 to 28 and n is 35 to 38.
21. A method of treating osteoporosis in a subject in need of said treatment, which comprises nasally administering to the subject an amount effective for the treatment of osteoporosis of a compound according to claim 2 in which m is 18 to 28 and n is 37 or 38.
22. A method of treating hypercalcemia, hyperparathyroidism, a disease state caused by a tumor or an aberrant cell overproducing a peptide hormone, or an immune disease in a subject in need of said treatment, which comprises administering to the subject a therapeutically amount of a compound according to claim 1.
PCT/US1993/007375 1992-08-05 1993-08-05 Parathyroid hormone fragments and analogs WO1994003201A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93919895A EP0656784A4 (en) 1992-08-05 1993-08-05 Parathyroid hormone fragments and analogs.
JP6505568A JPH08503692A (en) 1992-08-05 1993-08-05 Parathyroid hormone fragments and analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92607092A 1992-08-05 1992-08-05
US07/926,070 1992-08-05

Publications (1)

Publication Number Publication Date
WO1994003201A1 true WO1994003201A1 (en) 1994-02-17

Family

ID=25452700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007375 WO1994003201A1 (en) 1992-08-05 1993-08-05 Parathyroid hormone fragments and analogs

Country Status (4)

Country Link
EP (1) EP0656784A4 (en)
JP (1) JPH08503692A (en)
CA (1) CA2141588A1 (en)
WO (1) WO1994003201A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010041A1 (en) * 1994-09-28 1996-04-04 Forssmann Wolf Georg PEPTIDES FROM THE hPTH SEQUENCE (1-37)
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
WO2000038707A1 (en) * 1998-12-24 2000-07-06 Garvan Institute Of Medical Research Method for the treatment of bone loss
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7820393B2 (en) 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4203040A1 (en) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh NEW PARATHORMON FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0656784A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
WO1996010041A1 (en) * 1994-09-28 1996-04-04 Forssmann Wolf Georg PEPTIDES FROM THE hPTH SEQUENCE (1-37)
DE4434551A1 (en) * 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptides from the sequence of hPTH (1-37)
WO2000038707A1 (en) * 1998-12-24 2000-07-06 Garvan Institute Of Medical Research Method for the treatment of bone loss
US7943323B2 (en) 1999-01-14 2011-05-17 Scantibodies Laboratory, Inc. Methods for differentiating and monitoring parathyroid and bone status related diseases
US7892749B2 (en) 1999-01-14 2011-02-22 Scantibodies Laboratory, Inc. Methods for differentiating and monitoring parathyroid and bone status related diseases
US6743590B1 (en) 1999-01-14 2004-06-01 Scantibodies Laboratory, Inc. Methods for differentiating and monitoring parathyroid and bone status related diseases
US8329409B2 (en) 1999-01-14 2012-12-11 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US8298770B2 (en) 1999-01-14 2012-10-30 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US7723042B2 (en) 1999-01-14 2010-05-25 Scantibodies Laboratory, Inc. Methods for differentiating and monitoring parathyroid and bone status related diseases
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7384912B2 (en) 2002-01-10 2008-06-10 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Also Published As

Publication number Publication date
CA2141588A1 (en) 1994-02-17
EP0656784A1 (en) 1995-06-14
JPH08503692A (en) 1996-04-23
EP0656784A4 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
US6472505B1 (en) Peptide parathyroid hormone analogs
JP2944669B2 (en) Peptide, method for producing the same, LHRH antagonist containing the peptide
US5939386A (en) Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency
US4476116A (en) Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
EP0277829B1 (en) Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists
JP3164463B2 (en) Peptides
US5470828A (en) Peptide analogs of insulin-like growth factor II
SK7552001A3 (en) Controlled release formulation comprising gnrh-ii
WO1994003201A1 (en) Parathyroid hormone fragments and analogs
JPH0674279B2 (en) Growth hormone releasing factor analog and method for producing the same
US5783558A (en) Parathormone fragments, their preparation and medicaments containing these
MX2011010968A (en) Short-chain peptides as parathyroid hormone (pth) receptor agonist.
NL8901059A (en) ACID ADDITION SALTS OF AMIDATED TAURINE OR GLYCINE, METHODS FOR THEIR PREPARATION AND USE.
EP0773958A1 (en) PTH OR PTHrP ANTAGONISTS
EP0188214A2 (en) Novel growth hormone-releasing peptides and method of treating mammals therewith
JPH09506616A (en) Analogue of hGH-RH (1-29) NH 2) having antagonistic activity
JPH083196A (en) Calcitonin derivative and its use
EP0687270B1 (en) Osteogenic growth oligopeptides and pharmaceutical compositions containing them
Raisz et al. Comparison of the effects of a potent synthetic analog of bovine parathyroid hormone with native bPTH-(1-84) and synthetic bPTH-(1-34) on bone resorption and collagen synthesis
EP0384731B1 (en) Osteogenic growth polypeptides identified from regenerating bone marrow
JPH07316195A (en) New pthrp-related peptide and use thereof
EP2198878A1 (en) Polypeptide bombesin antagonists
RU2119800C1 (en) Growth hormone factor peptide analog and method and composition for stimulating growth hormone secretion
EP0288058A2 (en) Analogs of (1,7-di-alanine, des-19-leucine) calcitonine
WO2000024764A1 (en) Lhrh analogues for the treatment of osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2141588

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993919895

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993919895

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993919895

Country of ref document: EP